Wave Life Sciences Ltd (WVE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wave Life Sciences Ltd (WVE) has a cash flow conversion efficiency ratio of -0.116x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-59.55 Million) by net assets ($511.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See WVE equity to assets ratio to measure how much of total assets are equity-financed.
Wave Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Wave Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Wave Life Sciences Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Wave Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wave Life Sciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Expressway Company Limited
F:HU7
|
0.027x |
|
Sano Bruno's Enterprises Ltd
TA:SANO1
|
0.033x |
|
Central Plains Environment Protection Co Ltd
SHE:000544
|
0.014x |
|
SM Entertainment Co. Ltd
KQ:041510
|
0.045x |
|
Beijing Cuiwei Tower Co Ltd
SHG:603123
|
-0.003x |
|
Shandong Kaisheng New Materials Co.Ltd.
SHE:301069
|
N/A |
|
FARM FRESH BERHAD
KLSE:5306
|
0.064x |
|
Sify Technologies Limited
NASDAQ:SIFY
|
0.001x |
Annual Cash Flow Conversion Efficiency for Wave Life Sciences Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Wave Life Sciences Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Wave Life Sciences Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $526.23 Million | $-187.49 Million | -0.356x | +50.57% |
| 2024-12-31 | $209.51 Million | $-151.03 Million | -0.721x | -47.02% |
| 2023-12-31 | $39.63 Million | $-19.43 Million | -0.490x | -117.30% |
| 2022-12-31 | $-45.09 Million | $-127.78 Million | 2.834x | +203.48% |
| 2021-12-31 | $32.50 Million | $-88.99 Million | -2.738x | -114.04% |
| 2020-12-31 | $90.65 Million | $-115.98 Million | -1.279x | +51.33% |
| 2019-12-31 | $71.61 Million | $-188.23 Million | -2.629x | -743.37% |
| 2018-12-31 | $73.35 Million | $-22.86 Million | -0.312x | +47.92% |
| 2017-12-31 | $139.81 Million | $-83.67 Million | -0.598x | -153.23% |
| 2016-12-31 | $134.86 Million | $-31.87 Million | -0.236x | -189.57% |
| 2015-12-31 | $153.49 Million | $-12.53 Million | -0.082x | +96.26% |
| 2014-12-31 | $2.03 Million | $-4.43 Million | -2.184x | -577.29% |
| 2013-12-31 | $-7.76 Million | $-3.55 Million | 0.457x | -- |
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more